Charles joined SV in 2018 and is a Senior Associate in the biotech team. He helps form and fund companies developing transformational new medicines, with a broad focus from new company creation to later stage opportunities. Charles serves as a board observer at Autifony Therapeutics, EnaraBio, Pulmocide, Imbria Therapeutics,and Mestag Therapeutics which he also helped incubate and launch.
Charles identifies and evaluates new opportunities and advises portfolio company management on strategy, fundraising, and business development.
Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies.
Outside of SV, Charles is a keen chef, swimmer, and traveller.
MSci Human Genetics, University College London; specialization in the genetics of neurodegenerative disease and cancer biology. Chartered accountant (ACA).